Home > Corporate Compliance
As a company engaged in the challenging pursuit of finding solutions for progressive liver diseases with high unmet medical need, Intercept Pharmaceuticals, Inc. and its affiliated companies (Intercept) is committed to bringing positive impact on patients’ lives. As a good corporate citizen, in addition to focusing on WHAT our mission is, Intercept is committed to ensuring ethics, integrity and compliance in HOW we achieve our mission. As such, it is Intercept’s policy to conduct all aspects of our business in accordance with the highest standards.
As part of this commitment, Intercept has established a comprehensive Compliance Program in accordance with the principles set forth by the United States Department of Health and Human Services Office of Inspector General (OIG).
Compliance Oversight
Intercept has designated a Chief Compliance Officer (CCO), who is responsible for developing, overseeing, and monitoring the operation of our Compliance Program. Our CCO reports to the Head of Legal Affairs. The CCO has effective lines of communication with other departments of the company and has access to the Chief Executive Officer or, if required, the Board of Directors on compliance related matters. Intercept also established a Compliance Committee comprised of senior-level representatives from various functions across the company. The Compliance Committee is charged with oversight of Intercept’s Compliance Program and meets quarterly to review and develop action plans to address compliance related matters.
Policies and Procedures
Intercept has a publicly available Global Code of Business Conduct setting forth the company’s commitment to compliance by its management, employees and agents. Intercept also has internal policies in place requiring all relevant associates to comply with appropriate standards and legal requirements, such as laws, regulations, codes or other guidelines, as may be applicable in the jurisdictions in which we conduct business.
Where required, Intercept has implemented a $2,500 per healthcare professionals (HCP) per year limit on gifts, meals, promotional materials or other items they might receive from Intercept. These limits do not include the value of grants for medical education, medical scholarships, professional services, or other permitted items under the applicable rules and regulations.
Responding and Reporting
Intercept has a toll-free hotline any employee can use to make a report of suspicious activity, anonymously if desired. Employees must promptly report any violation of the Compliance Program or any policies of the company using any of the available company resources. Employees making good faith reports are protected from retaliation. Employees are permitted to cooperate with law enforcement and are required to refrain from taking any action to interfere with any ongoing investigation.
Training
Intercept employees are trained on issues contained on the Compliance Program, including compliance with the Global Code of Business Conduct, and how to report concerns. Refresher and update training is routinely given to employees covering issues relevant to the industry and interactions with HCPs.
Auditing, Monitoring and Discipline
Each operating function / department within Intercept has the authority to monitor and audit the activities of its employees and third parties for compliance with this Compliance Program. Should wrongdoing on the part of an employee be found, disciplinary action up to, and including, termination of employment may be taken.
Updates
This Compliance Program may be amended, altered or revised from time-to-time as needed and without prior notice.
Consistent with the requirements of California Health & Safety Code §§ 119400-119402, Intercept Pharmaceutical, Inc. (hereinafter “Intercept”) has established an aggregate limit on certain promotional expenditures that may be provided to individual medical and healthcare professionals (HCPs). Intercept has annual aggregate limit on covered promotional expenditures at $2,500 per covered HCPs for annual periods. This limit may be revised by Intercept from time to time. The foregoing limit does not represent any usual, customary, average, or typical amount for HCPs. Intercept exempts certain expenditures from this limit based upon a good faith understanding of California Health & Safety Code §§ 119400-119402 and the PhRMA Code.
Such exemptions include:
For the Annual Declaration of Compliance with California Health & Safety Code §§ 119400 – 119402 click here.
For the Statutory Price Disclosure Notice to Vermont Prescribers, click here.
For the Statutory Price Disclosure Notice to Colorado Prescribers, click here.
You are now leaving Intercept Pharmaceuticals’ corporate website and entering a site intended for U.S. audiences only.
You are now leaving Intercept Pharmaceuticals’ corporate website. Intercept does not control or endorse the content of this external site.
The link you have selected will take you outside of Intercept Pharmaceuticals’ corporate website.
The site you will be entering is intended for U.S. audiences only.
If you are a healthcare provider looking for product information, visit ocalivahcp.com.
You have selected a link that will take you to a site maintained by a third party who is solely responsible for its contents. Intercept provides this link as a service to its website visitors. Intercept is not responsible for the content or the privacy policy of any third party websites.
Close this window to return to Intercept Pharmaceuticals’ site or click ‘Continue’ to proceed.
United States (US)
European Union (EU)
Canada
Israel
Switzerland
Australia
Liechtenstein
United Arab Emirates (UAE)
Exploring Racial Differences and Disparities in PBC Care